Category: Andreas Hadjivasiliou

  • Evaluate’s Orphan Drug Report 2022

    Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within the orphan drug market and forecasts what the future of the industry holds based on data. Evaluate provides commercial intelligence to the pharma and life sciences sectors through […]